Auxesis Pharma Holding AB has been granted Small and Medium-sized Enterprise (SME) status as of January 23, 2024, by the European Medicines Agency (EMA). Obtaining SME status from EMA means that the company will have easier access to regulatory, financial, and administrative support from EMA throughout the development stages of its products.The SME status can be extended on an annual basis as soon as information regarding the company’s financial performance for the previous fiscal year has been reported to EMA.